Abstract-Renal denervation (RDN) has been shown to restore endogenous neuronal nitric oxide synthase (nNOS) in the paraventricular nucleus (PVN) and reduce sympathetic drive during chronic heart failure (CHF). The purpose of the present study was to assess the contribution of afferent renal nerves to the nNOS-mediated sympathetic outflow within the PVN in rats with CHF. CHF was induced in rats by ligation of the left coronary artery. Four weeks after surgery, selective afferent RDN (A-RDN) was performed by bilateral perivascular application of capsaicin on the renal arteries. Seven days after intervention, nNOS protein expression, nNOS immunostaining signaling, and diaphorasepositive stained cells were significantly decreased in the PVN of CHF rats, changes that were reversed by A-RDN. A-RDN reduced basal lumbar sympathetic nerve activity in rats with CHF (8.5%±0.5% versus 17.0%±1.2% of max). Microinjection of nNOS inhibitor L-NMMA (L-N G -monomethyl arginine citrate) into the PVN produced a blunted increase in lumbar sympathetic nerve activity in rats with CHF. This response was significantly improved after A-RDN (Δ lumbar sympathetic nerve activity: 25.7%±2.4% versus 11.2%±0.9%). Resting afferent renal nerves activity was substantially increased in CHF compared with sham rats (56.3%±2.4% versus 33.0%±4.7%). These results suggest that intact afferent renal nerves contribute to the reduction of nNOS in the PVN. A-RDN restores nNOS and thus attenuates the sympathoexcitation. Also, resting afferent renal nerves activity is elevated in CHF rats, which may highlight a crucial neural mechanism arising from the kidney in the maintenance of enhanced sympathetic drive in CHF. (Hypertension. 2018;72:667-675.
nhanced sympathetic nerve activity has been identified as a major contributor to the complex pathophysiology of chronic heart failure (CHF) both in experimental models and patients. 1, 2 Although most therapeutic pharmaceutical strategies target the peripheral symptoms of the disease, they may not influence the enhanced sympathetic nerve activity. The mechanisms for the enhanced sympathoexcitation observed in CHF are not fully understood. The paraventricular nucleus (PVN) of the hypothalamus is an important site that integrates and responds to a variety of neural and humoral signals regulating sympathetic drive and extracellular fluid volume status. 3, 4 In the PVN, PVN neurons projecting to the rostral ventrolateral medulla (RVLM) are more active in rats with CHF, suggesting that preautonomic neurons within the PVN are activated and contribute importantly in initiating sympathoexcitation in CHF. 5 Our previous studies have also shown that excitatory neurotransmission is enhanced whereas inhibitory neurotransmission via nitric oxide (NO) is reduced in rats with CHF. [6] [7] [8] [9] The kidneys are positioned to be the origin as well as target of sympathetic nervous system activation. 10 The discharge frequency of putative vasopressinergic magnocellular neurosecretory neurons in the PVN is increased during stimulation of afferent renal nerves (ARN) and during the activation of specific renal receptors. 11 Recently, we have shown that ARN stimulation activates the PVN neurons projecting to the RVLM. 12 Stimulation of ARN also increases sympathetic activity and arterial pressure. 12, 13 These observations suggest that afferent information from the kidney is important in the coordination of neural and humoral activity concerned with body fluid balance and the regulation of arterial blood pressure in normal and disease conditions. [14] [15] [16] [17] [18] CHF is associated with several symptoms that would be expected to stimulate renal afferent activity, such as reduced perfusion pressure, increased venous pressure, increased inflammation, and increased oxidative stress. 19 It is possible that a pathological positive feedback signal from the level of the kidney may exist, thereby causing an increase in overall sympathetic tone.
Renal denervation (RDN) has been shown to reduce arterial pressure and sympathetic outflow in patients with resistant hypertension and various animal models. [20] [21] [22] Transection of September 2018 aortic depressor nerve produced a chronic neurogenic hypertension in normotensive rats [23] [24] [25] [26] [27] [28] although it failed to raise blood pressure in spontaneously hypertensive rats. 29 RDN has been shown to decrease sympathetic activity and arterial pressure in this neurogenic hypertensive animal model. 30 Our previous study also shows that noradrenergic activity is altered in the hypothalamus after RDN, suggesting that the sympathoinhibitory effects of RDN are mediated centrally at the level of the hypothalamus. 31 Our recent study has shown that RDN restores endogenous neuronal NO synthase (nNOS) in the PVN and at the same time reduce sympathetic drive during CHF. 32 However, these studies were based on total RDN, where both ARN and efferent renal nerves were ablated. The present study was conducted to assess the role of ARN on altered nNOS within the PVN with concomitant increase in sympathetic outflow in rats with CHF. We hypothesized that the effects of afferent RDN (A-RDN) normalized endogenous nNOS in the PVN, as well as restored sympathetic outflow in rats with CHF. Resting ARN activity was substantially increased in CHF compared with sham rats. We proposed that enhanced ARN activity led to the enhanced activation of neurons in the PVN that translated ultimately to the activation of sympathetic nervous system in CHF.
Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Animals
All procedures used for this study were approved by University of Nebraska Medical Center Institutional Animal Care and Use Committee and conducted according to the National Institutes of Health guide for the Care and Use of Laboratory Animals, Eighth Edition, National Academies Press, 2011. Male Sprague-Dawley rats weighing 220 to 250 g were purchased from Sasco Breeding laboratories (Omaha, NE). Animals were housed with a 12-hour light-dark cycle at ambient 22°C 30% to 40% relative humidity. Laboratory chow and tap water were available ad libitum. After acclimatization for 1 week, rats were assigned randomly to 1 of 4 groups: sham, CHF, sham+capsaicin (CAP), and CHF+CAP (n=12-18/group).
Surgical Preparations
Rats were randomly assigned to either a sham-operated control group or a CHF group. CHF was produced by left coronary artery ligation, as previously described. 33 Four weeks after ligation surgery, rats underwent A-RDN under anesthesia (ketamine, 48 mg/kg; xylazine 12 mg/kg, IP). The experiments were performed at 1 week after A-RDN (5 weeks after the coronary ligation).
Statistical Analysis
Data were subjected to a 2-way ANOVA followed by a multiple range test (for multiple comparisons) or Student-Newman Keuls test. P<0.05 was considered to indicate statistical significance.
Specific Methods
Specific methods are available in the online-only Data Supplement. Table S1 in the online-only Data Supplement presents morphological characteristics and left ventricular function parameters among the 4 experimental groups, sham, CHF, sham+CAP, and CHF+CAP. The body weight and heart weight were significantly increased in CHF group compared with the sham group. A-RDN had no significant effects on the body weight and heart weight in sham and CHF groups. CHF rats had >30% infarcts of the left ventricular wall while sham rats had no visible myocardial damage. A-RDN did not change infarct size in CHF rats. Left ventricular end-diastolic pressure was significantly increased in the CHF rats compared with both sham groups and CHF+CAP group. Both +dP/dt and -dP/dt were significantly decreased in the both CHF and CHF+CAP rats compared with both sham groups. Left ventricular enddiastolic pressure was partially reduced by A-RDN while +dP/ dt and -dP/dt were not significantly affected by A-RDN. Figure 1A shows the immunohistochemistry images of 1 kidney without CAP and 1 kidney with CAP treatment. The kidney without CAP has significant amount of calcitonin gene-related peptide (CGRP) labeling in the renal pelvic wall while the CAP-treated kidney has little CGRP labeling. Furthermore, Western blot data showed similar pattern for reduction of CGRP protein in the renal pelvic wall in the CAP-treated kidney. CGRP protein expression was decreased 78% in CAP-treated rats ( Figure 1B ) compared with the rats without CAP treatment. There was no significant difference in tyrosine hydroxylase labeling and protein expression in the renal pelvic wall after CAP between the groups.
Results

General Characteristics
Validation of Afferent RDN by Immunohistochemistry and Western Blot
Serum Norepinephrine Concentration Measurements
Serum norepinephrine (NE) concentration used as an index of overall sympathetic activation was significantly greater in CHF rats compared with sham-operated controls. A-RDN by CAP reduced the serum concentration of NE in rats with CHF (377±54 pg/mL CHF+CAP versus 509±54 pg/mL CHF; P<0.05). There was no significant change in the sham rats with A-RDN, suggesting that the A-RDN did not change the NE concentration in control conditions ( Figure 2A ).
Renal pelvic NE content was significantly greater in CHF rats compared with sham-operated controls (7.9±0.9 versus 5.1±0.6 ng/g; P<0.05). A-RDN had no significant effects on the renal pelvic content of NE in both sham and CHF rats ( Figure 2B ).
NOS Activity (Diaphorase Staining) and Expression of nNOS (Immunohistochemistry and Protein) in the PVN
The number of positive cells for the NADPH (nicotinamide adenine dinucleotide phosphate)-diaphorase activity (as a marker of NOS activity) in the PVN was significantly decreased in CHF compared with the sham group (73±14 versus 29±12; P<0.05). This reduction in NOS activity was attenuated in the CHF rats after A-RDN (60±11 CHF+CAP versus 29±12 CHF; P<0.05; Figure 3 ). There was no significant difference in the number of NADPH-positive cells in the PVN after A-RDN between the sham and CHF groups.
Immunostaining signal for nNOS in the PVN was decreased in CHF compared with the sham group. This reduction in nNOS immunoreactivity was also attenuated in the CHF rats after A-RDN ( Figure 4A and 4B). Western blot data showed that nNOS protein expression was decreased 51% in CHF that was abrogated by A-RDN (0.95±0.20 CHF+CAP versus 0.46±0.11 CHF; P<0.05; Figure 4C ). There was no difference in nNOS protein expression in the PVN after A-RDN between the sham and CHF groups.
L-NMMA Microinjection Into the PVN
The basal lumbar sympathetic nerve activity (LSNA) was significantly increased in rats with CHF compared with the sham rats (17.0%±1.2% versus 8.5%±0.5% of max; P<0.05). A-RDN significantly reduced the basal LSNA in CHF group rats (8.7%±1.1% CHF+CAP versus 17.0%±1.2% of max CHF; P<0.05; Figure 5A ). Baseline LSNA was normalized by A-RDN. Inhibiting NOS with L-N G -monomethyl arginine citrate (L-NMMA) in the PVN increased LSNA in both sham and CHF groups as shown previously while recording renal sympathetic nerve activity. 7 The percentage change in LSNA to L-NMMA injection was blunted in CHF compared with sham (11%±2% versus 24%±2% at 200 pmol L-NMMA; P<0.05; Figure 5B and 5C). Mean arterial pressure and heart rate responses to L-NMMA injection were also attenuated in the CHF condition. After A-RDN, LSNA, mean arterial pressure, and heart rate responses were all normalized in CHF rats (LSNA: 26%±2% CHF+CAP versus 11%±2% CHF at 200 pmol L-NMMA; P<0.05).
Resting ARN Discharge in CHF Rats
Examples of recordings showing tracing of renal sympathetic nerve activity, resting ARN activity (ARNA) after sectioning of the proximal end of the nerve and background noise, from sham and CHF rats are shown in Figure 6A . The total renal sympathetic nerve activity was significantly increased in CHF rats compared with the sham rats (3.82±0.59 versus 1.78±0.08 μV.s; P<0.05; Figure 6C ). The resting ARNA was higher in CHF rats after section the proximal end of the renal nerve (1.62±0.27 versus 0.77±0.14 μV.s; P<0.05; Figure 6D ). The peak response to intrapelvic CAP was not significantly different between the sham and CHF groups (2.96±0.60 versus 2.28±0.16 μV.s; P>0.05; Figure 6B and 6E). Final resting ARNA was expressed as percentage of peak ARNA response to intrapelvic CAP (%Amax). Resting ARNA was significantly higher in CHF rats compared with the sham rats (56.3%±2.4% versus 33.0%±4.7% Amax; P<0.05; Figure 6F ).
Discussion
The present study shows that A-RDN by CAP abrogates the increase in lumbar sympathetic outflow and elevated plasma NE in CHF. At the same time, A-RDN restored the endogenous nNOS in the PVN that had been decreased in rats with CHF. Consistent with these observations, RDN normalized the blunted LSNA response to inhibition of endogenous nNOS within the PVN observed in CHF rats. Furthermore, we found that the resting ARN activity was increased in CHF rats. These results demonstrate a critical role for the PVN in relaying neural signals from the kidney that may be tonically active in the CHF condition and are abrogated by specific A-RDN. A possible mechanism for the therapeutic effects of A-RDN during CHF on sympathetic outflow may be through an NO-dependent mechanism within the PVN.
Selective Ablation of ARNs
Recently, a novel method of selective ablation of ARN by periaxonal application of CAP has been reported. [34] [35] [36] An adapted technique was performed by exposure of the renal nerves to CAP causing ablation of afferent but not efferent renal nerves. CAP ablates small unmyelinated C-fibers and destroys afferent neurons in the kidney. 37 Using similar technique, we applied CAP to the surface of renal artery and vein to ablate renal afferent nerve in both sham and CHF rats. Seven days after intervention, CAP-treated rats had significantly depleted levels of an afferent nerve marker CGRP in the renal pelvis, as confirmed by immunohistology and Western blot. CAP application had no effect on renal pelvic content of the efferent nerve markers tyrosine hydroxylase and NE. These results demonstrate and confirm that CAP caused A-RDN [34] [35] [36] effectively ablating ARN but having no effect on intact efferent renal nerves in rats.
Renal Afferent Denervation Normalizes the Sympathoexcitation in CHF
Exaggerated sympathoexcitation is characteristic of both hypertension and CHF. RDN has been shown to reduce arterial pressure and sympathetic activity in experimental forms of hypertension, as well as drug resistant hypertensive patients. 20, 21, 38 In our previous studies, bilateral surgical RDN known to remove both ARN and efferent renal nerve was sufficient to reduce overall sympathetic outflow, as evident by a reduction in urinary excretion of NE as well as basal level of LSNA. 32 The results from the present study show that A-RDN by CAP similarly reduced the basal LSNA and serum NE levels in CHF rats while having no significant effects on serum NE levels in the sham rats. A-RDN did not reduce the kidney pelvic NE content in both sham and CHF rats, suggesting that the efferent component of the renal nerves was intact after CAP treatment. Our results suggest that A-RDN reduces sympathetic outflow by ablation of ARN that does not disrupt efferent renal nerves.
The present data show that the body weight, whole heart weight, and infarct size were significantly increased in the CHF group. A-RDN had no significant effects on these parameters in both sham and CHF groups. However, left ventricular end-diastolic pressure was significantly reduced by A-RDN while +dP/dt and -dP/dt were not significantly affected by A-RDN. The data confirm that the rats in the CHF groups were experiencing cardiac dysfunction and that A-RDN partially improved left ventricular function by restoring left ventricular end-diastolic pressure. It is possible that the damage induced by coronary artery ligation is fairly severe and prevalent for 4 weeks, which are difficult to reverse with reduction in sympathetic outflow mediated by A-RDN. Nevertheless, overall, these data are consistent with our previous study showing that total RDN (ablation of both afferent and efferent renal nerves) improved cardiac function in rats with CHF.
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PVN and Activated Renal Afferent Nerve Signal
Several studies indicate that the renal afferent information is transmitted to sites within the spinal cord that relay information to the central nervous system associated with cardiovascular regulation, including nucleus tractus solitarius, RVLM, preoptic area, subfornical organ, lateral hypothalamus, and the PVN in the hypothalamus. 16, 18, 40 The PVN is an important site that integrates and responds to a variety of neural and humoral signals regulating sympathetic drive and extracellular fluid volume. 3, 41, 42 Previous studies including ours have demonstrated that the discharge frequency of preautonomic neurons in the PVN was increased during stimulation of ARN. 11, 32 We have found that electrical stimulation of the ARN activated RVLM projecting PVN neurons to a greater extent in rats with CHF than sham rats. 32 These data suggest that afferent signal from the kidneys of CHF rats are more potent than those in sham rats in eliciting activation of preautonomic neurons within the PVN. We also found that basal activity of RVLM projecting PVN neurons is increased in CHF rats, 5 suggesting that perhaps there is a potential tonic activation by the ARN during CHF condition, which may contribute to an increased overall sympathoexcitation under basal conditions.
To examine whether the renal afferents are activated tonically in the CHF condition, in the present study, we directly recorded baseline ongoing renal afferent activity in both sham and CHF rats. Resting ARN activity, expressed as a percent of peak ARN activity, was substantially increased in CHF compared with the sham rats. This is direct evidence to support the idea that there is enhanced afferent activity from the kidneys of CHF rats compared with the sham rats. There is other evidence to suggest that the diseased kidneys may exert an excitatory effect on sympathetic nerve activity in various pathological conditions involving renal injury, including hypertension, CHF, chronic renal failure, diabetes mellitus, and obesity. 10, 16, [43] [44] [45] [46] Because renal inflammation is prevalent in many of these pathological conditions, it is tempting to speculate that such a signal may contribute to the increased sympathetic outflow via activation of ARN in rats with CHF.
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Renal Afferent Denervation Improves nNOS Expression and Functional NOS Activity in the PVN During CHF NO, well-known to inhibit neuronal activity, is decreased in the PVN during CHF. 47, 48 Sympathoexcitatory and hemodynamic responses to endogenous blockade of NO within the PVN were impaired in CHF, 7 suggesting that the PVN contributes to the increased sympathoexcitation exhibited in CHF via an altered NO mechanism. Our results show that A-RDN by CAP restores the levels of nNOS within the PVN of rats with CHF, suggesting that A-RDN re-establishes the endogenous inhibitory nNOS mechanisms in rats with CHF. Furthermore, the levels of diaphorase-positive cells are also restored in rats with CHF, suggesting that the NOS activity index is normalized after A-RDN. The functional activity of NOS within the PVN of rats with CHF is also re-established. The improved LSNA responses to microinjection of L-NMMA into the PVN are concomitant with enhanced nNOS levels in the PVN of rats with CHF after A-RDN. The amended central nNOS mechanism/s within the PVN in turn would alleviate the enhanced sympathoexcitation in rats with CHF. Taken together, the improvement in centrally mediated sympathoinhibition by A-RDN seems to be mediated via the nitroxidergic mechanism within the PVN. The source of this signal or its modality seems to be associated with ARN, but the salient characteristics of this signal remain to be identified.
Perspectives
Although RDN has been shown to lower arterial pressure in some humans with resistant hypertension, possibly by reducing overall sympathetic outflow, a similar effect in CHF is not conclusively established. In a safety trial, RDN in patients with CHF showed that there was no significant reduction in systolic pressure but improved 6-minute walk distance. 49 Further in a pilot study, RDN showed a reduction in ventricular tachyarrhythmias in patients with CHF. 50 Furthermore, RDN in hypertensive patients with cardiomyopathy have been shown to have reduced left ventricular mass 51, 52 and increased ejection fraction. 52 Previously, we have demonstrated that RDN in rats with CHF reduces centrally mediated sympathetic tone, specifically by the nNOS mechanism within the PVN. 32 However, it is not known whether the inhibitory effect is because of ablation of afferent or efferent renal nerves. One well-known function of the renal nerves is to stimulate renin release from the kidney, and renal nerve activity has been reported to be elevated in CHF. 38, 53 It is conceivable that this activation of efferent renal nerves may be causally related to increased levels of angiotensin II in CHF. It has also been shown previously that angiotensin II causes an increased activation of the sympathetic activation via the PVN in CHF. [54] [55] [56] Furthermore, we have observed that angiotensin II may also cause a decrease in levels of nNOS in vitro, as well as in the PVN of rats with CHF. 57 Consequently, it is conceivable that the changes in the PVN are influenced by the elimination of this angiotensin II component by removal of renal efferent nerves.
Therefore, it is crucially important to address (1) whether ARN are involved in the sympathoexcitatory state in CHF, (2) if they are involved, whether we can target ARN specifically to optimize the efficacy and reduce the possible side effects of RDN, and (3) whether we can identify specific central sites and molecular mechanisms that can be targeted therapeutically. As a first step toward addressing these points, we have selectively ablated the ARN in rats with CHF. This procedure, termed RDN by CAP, effectively ablated ARN and restored nNOS levels within the PVN of rats with CHF and concomitantly reduced enhanced sympathetic tone. These results suggest that ARN may be critically involved in sympathoexcitation of CHF, making ARN both an important subject for future basic science research, as well as a possible target for human CHF. Further studies will be needed to determine the mechanisms underlying this antisympathoexcitatory effect, but one likely possibility is restoration of nNOS within the PVN. Understanding the inhibitory factors at the level of the kidney and central mechanisms underlying the reduction in central sympathetic drive may be critical to our understanding of the therapeutic effects of RDN and to the development of more targeted treatments.
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